Emcure Pharma, BHEL, Fractal Analytics among buzzing stocks; SENSEX recovers 400 pts, NIFTY above 23,850

The Indian benchmark indices, SENSEX and NIFTY50, were trading in positive territory on Wednesday, November 4, amid buying in realty and defence stocks. Investor sentiment also improved due to lower crude oil prices and a pullback in US Treasury yields.

However, Asian markets crashed during Wednesday’s trading session amid the overall dented sentiment of an AI trade reversal, resulting in a mass market selloff in equities, and as the US midterm election vote count weighed heavily towards the Democratic side

The SENSEX rallied as much as 0.6% to hit an intraday high of 77,396.04 in early trade. Meanwhile, the NIFTY50 gained as much as 0.57% to touch the session’s peak of 23,946.35.

At 1:18 PM, the S&P BSE SENSEX climbed by 129.40 points, or 0.17%, to trade at 77,047.25, while NSE’s NIFTY50 stood at 23,856.40, reflecting a 45.55-point, or 0.19% jump.

The indices had briefly tumbled into the red zone before recovering and rising back to positive territory. SENSEX recovered over 400 points from its intraday low.

The NIFTY50 index was supported by gains in Bharat Electronics, Adani Enterprises, Max Healthcare Institute, ITC Ltd, Titan Company, and Adani Ports and Special Economic Zone, which were among the top winners.

Conversely, the top losers included Tata Consultancy Services (TCS), Infosys, BSE Ltd, Eternal, and HCL Technologies.

Buzzing stocks on March 25: Check list

Shares of Emcure Pharmaceuticals gained as much as 10% to hit a fresh 52-week high of ₹2,174.20 per unit on the National Stock Exchange (NSE) on Wednesday, November 4, a day after reporting strong earnings for the second quarter of the 2026-27 financial year (Q2 FY27).

The company witnessed broad-based growth in its revenue, profitability and earnings, and expects to sustain its business momentum in the second half of the current fiscal year (H2 FY27). Analysts also noted that the company raised its revenue growth guidance to over 20% for FY27.

The stock Bharat Heavy Electricals Ltd (BHEL) jumped as much as 6.32% to ₹425.30 on the NSE, after the company announced that it had received orders from Adani Power for four projects involving 2x800 MW units each.

The contracts, valued at ₹5,000 crore–₹7,000 crore apiece, translate into a total estimated order value of ₹20,000 crore–₹28,000 crore, excluding GST.

Multi-Commodity Exchange of India (MCX) shares declined nearly 7% to hit an intraday low of ₹3,252 apiece on November 4, as investors booked profits, exercising selling pressure after the company’s strong financial performance in the July to September quarter results for the financial year 2026-27.

In the Q2 results, Multi Commodity Exchange of India recorded a 130% year-on-year (YoY) growth in the company’s consolidated net profit (attributable to owners) to ₹455 crore, in comparison to ₹197 crore in the corresponding quarter of the previous fiscal year.

Zydus Lifesciences stock declined as much as 4.7% to reach the session’s low of ₹1,182.40 per equity share on the NSE, as it saw its consolidated net profit fall 26.57% YoY to ₹926 crore in Q2 FY27, compared with ₹1,261 crore in the year-ago period.

Fractal Analytics stock advanced as much as 14% to touch an intraday high of ₹834.90 per equity share on Wednesday, after the firm reported a net profit of ₹81 crore in Q2 FY27, compared to ₹34 crore reported in the same period of the previous fiscal year, registering a 138% growth.

The company’s revenue from operations jumped 20% on a YoY basis to ₹957 crore in the June to September quarter as against ₹799 crore seen in Q2 FY26. On a constant currency (CC) basis, it increased 10% YoY.

“We are building Fractal for that moment, and this quarter shows it: revenue crossed $100 million and net income more than doubled,” said Srikanth Velamakanni, Co-founder and Group CEO, Fractal Analytics.

Linde India shares jumped as much as 8.4% to reach the session’s peak of ₹6,338.50 per unit on the NSE on November 4, as it reported its earnings for Q2 FY27.

The stock rose despite the company posting a consolidated net profit of ₹118.81 crore in the three months ended September 30, 2026, marking a 30.5% YoY decline from ₹171 crore in the same period last year.

However, its revenue from operations rose 12.3% YoY to ₹723 crore for the reporting quarter, as against ₹644 crore in the second quarter of FY26.

The stock of Lupin climbed as much as 2.3% to hit an intraday high of ₹2,062.10 per equity share, despite posting a 22.19% YoY fall in its consolidated net profit to ₹1,155.30 crore in the September quarter, dragged down by an exceptional item.

The company had posted a net profit of ₹1,484.83 crore in the corresponding period of the previous fiscal year, it said in a regulatory filing to the exchanges.

Its revenue from operations was ₹7,827.26 crore during the quarter under review, up 11.1% YoY from ₹7,047.51 crore in the year-ago period, it said.

The shares rose as much as 5.5% to touch the session’s peak of ₹1,036 apiece, as the super speciality hospital chain on Tuesday reported a 17.45% rise in consolidated net profit to ₹48.45 crore during the September quarter. It had posted a profit of ₹41.25 crore in the year-ago period, according to a regulatory filing.

Its revenue from operations jumped to ₹431.42 crore during the period under review, as against ₹28.3 crore in Q2 FY26.

"Our quarterly revenue and profits have nearly tripled since our listing in 2023, reflecting our consistent record growth quarter-over-quarter. Our acquisitions since listing have also progressed strongly, now contributing 28% of group revenue and achieving EBITDA breakeven within a short period," Yatharth Tyagi, Whole Time Director, Yatharth Hospitals, said.

M.K.Sons Fine Jewels shares made a decent stock market debut on Wednesday, November 4. Shares of the retail-focused jewellery company were listed at ₹171 apiece on the NSE, reflecting a premium of 5.5% over the initial public offering (IPO) issue price of ₹162 apiece.

On the BSE, M.K.Sons Fine Jewels stock started trading at ₹171.6, up 5.9% from the issue price.